Innovative Medical Devices Healionics specializes in developing synthetic biomaterial-based devices such as STARgraft, which addresses critical issues in dialysis access, presenting a strong opportunity for partnerships or sales to companies focused on dialysis technology, vascular access devices, or broader medical device markets.

Strong Clinical Validation The company has presented 24-month clinical results for STARgraft at prominent symposiums like CiDA, demonstrating product efficacy and safety, which could facilitate sales conversations with hospitals, clinics, and healthcare providers seeking proven, innovative solutions.

FDA Breakthrough Designation With the FDA granting Breakthrough Device status to STARgraft, Healionics gains faster regulatory pathways and increased credibility, creating an attractive entry point for medical distributors and healthcare institutions looking for innovative, approved vascular access solutions.

Strategic Funding & Recognition Recent investments and awards, including over $5.5M in Series A funding and the Luis Villalobos Award, signal strong investor confidence and technological validation, offering sales teams leverage when engaging healthcare providers and system purchasers interested in cutting-edge biomedical innovations.

Market Expansion Potential With a focus on vascular access failure affecting over 550,000 U.S. kidney failure patients, Healionics is positioned for significant market penetration, making it a compelling partner for organizations involved in dialysis treatment infrastructure, home care, and medical supplies dedicated to kidney health.